Stock Track | Kiniksa Pharmaceuticals Soars 7.77% Pre-Market on Q2 Earnings Beat and Raised 2025 Guidance

Stock Track

Jul 29, 2025

Shares of Kiniksa Pharmaceuticals Ltd. (KNSA) surged 7.77% in pre-market trading on Tuesday following the company's strong second-quarter 2025 financial results and increased full-year guidance. The biopharmaceutical firm, which focuses on developing and commercializing novel therapies for patients with debilitating autoimmune and autoinflammatory diseases, impressed investors with its performance and optimistic outlook.

Kiniksa reported Q2 2025 earnings per share (EPS) of $0.23, surpassing the analyst estimate of $0.18. The company's revenue also exceeded expectations, coming in at $156.797 million, well above the projected $145.218 million. This strong financial performance was driven by robust product sales, particularly from its flagship drug ARCALYST.

In a significant move that likely contributed to the stock's pre-market rally, Kiniksa raised its full-year 2025 guidance for ARCALYST net product revenue. The company now expects ARCALYST to generate between $625 million and $640 million, up from the previous guidance of $590 million to $605 million. This upward revision suggests growing confidence in the drug's market penetration and commercial success. Additionally, Kiniksa announced the initiation of a Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis, with Phase 2 data expected in the second half of 2026, indicating progress in its pipeline development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1118024079"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118024079\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118024079?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-29 19:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118024079","market":"nz","top_or_hot":-1,"title":"Stock Track | Kiniksa Pharmaceuticals Soars 7.77% Pre-Market on Q2 Earnings Beat and Raised 2025 Guidance","media":"Stock Track","content":"<p>Shares of Kiniksa Pharmaceuticals Ltd. (KNSA) surged 7.77% in pre-market trading on Tuesday following the company's strong second-quarter 2025 financial results and increased full-year guidance. The biopharmaceutical firm, which focuses on developing and commercializing novel therapies for patients with debilitating autoimmune and autoinflammatory diseases, impressed investors with its performance and optimistic outlook.</p>\n\n<p>Kiniksa reported Q2 2025 earnings per share (EPS) of $0.23, surpassing the analyst estimate of $0.18. The company's revenue also exceeded expectations, coming in at $156.797 million, well above the projected $145.218 million. This strong financial performance was driven by robust product sales, particularly from its flagship drug ARCALYST.</p>\n\n<p>In a significant move that likely contributed to the stock's pre-market rally, Kiniksa raised its full-year 2025 guidance for ARCALYST net product revenue. The company now expects ARCALYST to generate between $625 million and $640 million, up from the previous guidance of $590 million to $605 million. This upward revision suggests growing confidence in the drug's market penetration and commercial success. Additionally, Kiniksa announced the initiation of a Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis, with Phase 2 data expected in the second half of 2026, indicating progress in its pipeline development.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Kiniksa Pharmaceuticals Soars 7.77% Pre-Market on Q2 Earnings Beat and Raised 2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Kiniksa Pharmaceuticals Soars 7.77% Pre-Market on Q2 Earnings Beat and Raised 2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-07-29 19:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Kiniksa Pharmaceuticals Ltd. (KNSA) surged 7.77% in pre-market trading on Tuesday following the company's strong second-quarter 2025 financial results and increased full-year guidance. The biopharmaceutical firm, which focuses on developing and commercializing novel therapies for patients with debilitating autoimmune and autoinflammatory diseases, impressed investors with its performance and optimistic outlook.</p>\n\n<p>Kiniksa reported Q2 2025 earnings per share (EPS) of $0.23, surpassing the analyst estimate of $0.18. The company's revenue also exceeded expectations, coming in at $156.797 million, well above the projected $145.218 million. This strong financial performance was driven by robust product sales, particularly from its flagship drug ARCALYST.</p>\n\n<p>In a significant move that likely contributed to the stock's pre-market rally, Kiniksa raised its full-year 2025 guidance for ARCALYST net product revenue. The company now expects ARCALYST to generate between $625 million and $640 million, up from the previous guidance of $590 million to $605 million. This upward revision suggests growing confidence in the drug's market penetration and commercial success. Additionally, Kiniksa announced the initiation of a Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis, with Phase 2 data expected in the second half of 2026, indicating progress in its pipeline development.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KNSA","symbol_name":"Kiniksa Pharmaceuticals Ltd.","start_time":0,"source_url":"","article_id":"1118024079","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118024079","pubTimestamp":1753789459,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Kiniksa Pharmaceuticals Ltd. (KNSA) surged 7.77% in pre-market trading on Tuesday following the company's strong second-quarter 2025 financial results and increased full-year guidance. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KNSA":"Kiniksa Pharmaceuticals Ltd."},"translate_title":"股票追踪|Kiniksa Pharmaceuticals盘前飙升7.77%，第二季度盈利好于预期并上调2025年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KNSA":1},"content_text":"Shares of Kiniksa Pharmaceuticals Ltd. (KNSA) surged 7.77% in pre-market trading on Tuesday following the company's strong second-quarter 2025 financial results and increased full-year guidance. The biopharmaceutical firm, which focuses on developing and commercializing novel therapies for patients with debilitating autoimmune and autoinflammatory diseases, impressed investors with its performance and optimistic outlook.\nKiniksa reported Q2 2025 earnings per share (EPS) of $0.23, surpassing the analyst estimate of $0.18. The company's revenue also exceeded expectations, coming in at $156.797 million, well above the projected $145.218 million. This strong financial performance was driven by robust product sales, particularly from its flagship drug ARCALYST.\nIn a significant move that likely contributed to the stock's pre-market rally, Kiniksa raised its full-year 2025 guidance for ARCALYST net product revenue. The company now expects ARCALYST to generate between $625 million and $640 million, up from the previous guidance of $590 million to $605 million. This upward revision suggests growing confidence in the drug's market penetration and commercial success. Additionally, Kiniksa announced the initiation of a Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis, with Phase 2 data expected in the second half of 2026, indicating progress in its pipeline development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}